In a randomised, double-blind, placebo-controlled study, treatment with VYDURA* demonstrated a reduction in monthly migraine days (MMDs) at Weeks 9 through 12. Efficacy was sustained for up to 12 months in the open-label extension period.¹ 

Post hoc analysis of an exploratory endpoint. The analysis of this endpoint at Week 1 was not tested in hierarchical order or adjusted for multiplicity. Subjects had ≥1 day of efficacy data in the observation period and ≥1 week in the double-blind treatment phase.^3,4

There was a greater reduction in the number of migraine days during the first month of treatment compared to placebo (-2.9 vs -1.7, P<0.0001, nominal P value, and not controlled for multiplicity).² 

• Efficacy was sustained for up to an additional 12 months during the open-label study extension in which patients received VYDURA¹*
• In these patients, the overall mean reduction from baseline in the number of MMDs averaged over the 16-month treatment period was 6.2 days¹

* This study evaluated a rimegepant 75 mg tablet formulation bioequivalent to VYDURA.